Public Sector Pension Investment Board Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Public Sector Pension Investment Board grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,341 shares of the biopharmaceutical company’s stock after buying an additional 500 shares during the period. Public Sector Pension Investment Board’s holdings in Regeneron Pharmaceuticals were worth $4,563,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in REGN. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after purchasing an additional 96,266 shares during the last quarter. TD Asset Management Inc increased its position in shares of Regeneron Pharmaceuticals by 30.4% during the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after purchasing an additional 82,034 shares during the last quarter. Icon Wealth Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Regeneron Pharmaceuticals by 86.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 144,865 shares of the biopharmaceutical company’s stock worth $152,257,000 after buying an additional 67,235 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:REGN opened at $750.22 on Monday. The firm has a market capitalization of $82.44 billion, a P/E ratio of 18.57, a P/E/G ratio of 2.89 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a 50 day moving average price of $905.64 and a 200-day moving average price of $1,019.64. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20.

Analyst Upgrades and Downgrades

A number of brokerages have commented on REGN. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,107.29.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.